Tagged with MEA

MEA A selection of top stories coming out of the Middle East and Africa’s pharma sector: Egypt’s Gypto Pharma partners with US drugmaker Dawa to expand the local production of medicines; Jordan’s Hikma makes a USD 1 billion investment pledge for US manufacturing and R&D, and Riyadh-headquartered private equity firm Jadwa…

Saudi Arabia Localising the production of medicines has become a core priority for the Saudi government over the past decade as it attempts to increase national health security, create highly skilled jobs, and grow the non-oil economy. Multinational innovators now have a wide range of incentives (as well as enforcement tactics) to…

Saudi Arabia With Saudi Arabia striving to position itself as a regional leader in biopharmaceutical R&D by 2030 and to cement itself as a global hub before 2040, there has been a coordinated attempt to align research centres across the country under a unified national framework. This National Biotech Strategy, unveiled by…

Saudi Arabia Saudi Arabia has long represented an alluring marketplace for the global MedTech industry. Not only does the Kingdom constitute the largest spender on healthcare across the Middle East and North Africa region, but its medical device sector has been experiencing consistent compound annual growth rates of over six percent and…

Saudi Arabia Eye health is vital to everyday life, yet it remains heavily underfunded compared to fields like cancer or diabetes. While global spending on oncology is set to reach USD 440 billion by 2028, ophthalmology will receive just USD 38 billion, according to IQVIA. This gap is striking given the growing…

Saudi Arabia With increased average disposable income in Saudi Arabia eliciting more sedentary lifestyles and less healthy dietary choices, more than 68 percent of all mortality in the Kingdom is nowadays attributed to non-communicable diseases (NCDs). Not only does this come at immense cost to the public purse, but also presents a…

Saudi Arabia When it was first initiated back in 2016, in the wake of the launch of Vision 2030, few industry insiders could have anticipated just quite how radical Saudi Arabia’s Health Sector Transformation Program (HSTP) would turn out to be. Since then, several significant milestones have been reached – the retreat…

Saudi Arabia Saudi Arabia’s pharmaceuticals market grew an impressive 9.1 percent in 2024 underscoring its position as the regional heavyweight, and projecting a sales value of around USD 11.6 billion, which constitutes approximately 32 percent of the total share of the Middle East and Africa (MENA) region in the global marketplace. Yet…

Saudi Arabia Saudi Arabia’s pharmaceutical sector continues its impressive growth leadership within the region. With a 9.1 percent market growth in 2024 and a projected USD 11.6 billion in sales, the Kingdom now commands nearly a third of the entire MENA pharma market. But this story goes far beyond impressive numbers. Through…

Saudi Arabia Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact on health, societies, and economies is enormous. Moreover, over 90 percent of rare diseases have no known treatment, and rare disease patients often face delayed diagnoses and…

Saudi Arabia Saudi Arabia is rapidly emerging as a leader in digital healthcare, where AI, cloud computing, and data-driven solutions are reshaping the industry. Mohammed Saleh, Health Director Part of Microsoft EMEA, shares how Microsoft is driving this transformation – enhancing patient care, streamlining operations, and enabling AI-powered clinical advancements. With a…

Saudi Arabia Mohamed Ayad, representing Santen as the Head of the Middle East, discusses the Japanese multinational firm’s growing presence and strategic focus in the region. He shares insights into the challenges and opportunities within the eye health care and ophthalmology market, Santen’s innovative approach to product offerings, and the company’s commitment…